All weight loss and GLP-1 medications require a valid prescription from a licensed U.S. prescriber that matches the order exactly. Canada Drugs Online reserves the right to refuse any order if the prescription appears falsified, altered, incomplete, or otherwise invalid. For more information, please review our Prescription Approval Policy.
Modern weight management has been transformed by GLP-1 receptor agonists, which address the biological drivers of hunger and glucose regulation. These clinical therapies provide a multi-faceted approach to chronic weight management when combined with dietary and lifestyle modifications.[1]
We help Americans access lower prices on high-demand prescriptions, including medications like Wegovy, Ozempic, Zepbound, Mounjaro, Rybelsus, and Saxenda.
Weekly injectable therapies designed for potent appetite suppression and glucose regulation
Daily oral semaglutide options for patients seeking clinical metabolic support without needles
Long-term pharmacological support for sustainable weight management under medical supervision
Synergistic care for patients managing weight-related comorbidities such as Type 2 Diabetes
Only a fraction of state Medicaid programs currently provide coverage for obesity GLP-1 medications.[6]
Among firms not covering GLP-1s, only 1% are very likely to add coverage within the next 12 months.[6]
While the 2026 Bridge program helps some, coverage gaps remain for the broader self-paying population.[6]
Even with "coverage," utilization controls often create significant friction in fulfilling GLP-1 prescriptions locally.
| Medication | U.S. List Price Guide | Our Price | Potential Monthly Savings |
|---|---|---|---|
 | $1,349.02 / month | $599.99 | $749.03 |
 | $1,027.51 / month | $329.99 | $697.52 |
 | $1,059.87 / month | $499.99 | $559.88 |
 | $1,112.16 / month | $499.79 | $612.37 |
 | $997.58 / month | $299.79 | $697.79 |
Pricing snapshots are for educational purposes based on manufacturer list data vs. current globally licensed source pricing. [7]
Weight management with GLP-1s like Wegovy or Zepbound is clinically considered chronic therapy. Reducing or stopping medication without provider guidance often leads to weight regain. Consistent refill access is critical to maintaining metabolic progress.[1]
Of U.S. adults had obesity during the 2021-2023 tracking period, highlighting the metabolic crisis.
Source: CDC [6]Number of Americans seeking pharmacological assistance for metabolic weight management annualy.
Source: CDC / KFF [6]Prevalence of adult obesity in every single U.S. state and territory monitored in 2024.
Source: CDC [6]
